The AlphaLISA® immunoassay kit for human lactate dehydrogenase subunit A (LDHA) enables the quantitative determination of human LDHA in cell lysates and serum using a homogeneous AlphaLISA assay (no wash steps). Please note this is NOT a cell cytotoxicity assay, as the assay does not measure secreted LDH.
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Please note this is NOT a cell cytotoxicity assay. Formats:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Lactate Dehydrogenase A subunit (LDHA) is one subunit of lactate dehydrogenase, which is a tetramer of A and B subunits. Subunit A is mainly present in muscles, where it plays a key role in energy metabolism by catalyzing the oxidation of pyruvate into lactate to produce energy in absence of oxygen. The enzyme is ubiquitous in cells playing the same metabolic functions. Elevation of the enzyme levels in cells is a known marker of many cancers, while its elevation in cell culture media is indicative of cell death. This detection kit is designed to quantify LDHA in serum and cell lysates.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.